The global botulinumtoxin (BNT) market is expected to
reach a value of USD 7.3 billion by 2025. The constant introduction of
innovative products for enhancement of aesthetic appeal supporting minimally
invasive aesthetic treatments is the prime factor driving the growth of the
market.
In addition, rapid growth of the sector is
attributed to the rising demand for minimally invasive or non-invasive
procedures. These procedures provide advantages such as small incision, shorter
hospital stay and rapid wound healing, and hence lead to larger acceptance and
demand. In addition, availability of wide variety of minimally invasive or
non-invasive treatment options is pushing the global botulinum toxin market
towards growth.
Also, the successful completion of research
projects is expected to expand the applications of presently approved products.
Companies are trying to widen the application of botulinum toxin in therapeutic
area through various research activities. For instance, Botox by Allergan
received the U.S. FDA approval for the treatment of strabismus (crossed eyes)
and blepharospasm associated with dystonia in 1989. Furthermore, in 2004, Botox
was approved by the U.S. FDA for hyperidrosis, cervical dystonia, upper limb
spasticity, chronic migraine and urinary incontinence in 2009, 2010 and 2011
respectively. Hence, these factors all together will aid in boosting the growth
of BNT sales during the forecast period.
Browse full report by Grand View
Research : http://www.grandviewresearch.com/industry-analysis/botulinum-toxin-market
Further Key Findings from the Study Suggest:
·
The rapid adoption of minimally invasive
treatment is augmenting the growth of neurotoxins market.
·
The botulinum toxin type A segment
accounted for the largest share in 2015 and is also anticipated to be the
fastest growing segment during the forecast period
·
In 2015, North America dominated the global
space with the largest revenue share owing to high demand for minimally
invasive or non-invasive aesthetic treatments
·
Asia Pacific is expected to emerge as the
fastest growing region during the forecast period, mainly due to growing social
awareness regarding anti-wrinkle procedures in India, China, and Japan
·
Major players competing in this market
include but are not limited to Allergan, Inc.; Ipsen Group; Merz GmbH and Co.
KGaA, Medytox,Inc.; US Worldmed, LLC; Lanzhou Institute of Biological Products.
Co.Ltd. and Revance Therapeutics, Inc.
Browse more reports of this category by Grand View
Research: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
botulinum toxin market by type, end use, and region:
Product Type Outlook (Revenue, USD Million; 2013 - 2025)
·
Botulinum Toxin Type A
·
Botulinum Toxin Type B
End Use Outlook (Revenue, USD Million; 2013 - 2025)
·
Therapeutic
·
Aesthetic
Regional Outlook (Revenue, USD Million; 2013 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o UK
·
Asia Pacific
o China
o Japan
·
Latin America
o Mexico
o Brazil
·
MEA
o South Africa
View press
release of this research report by Grand View Research: https://www.grandviewresearch.com/press-release/global-botulinum-toxin-market
About Grand
View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.